Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > AlphaRx Appoints Leading Infectious Disease Specialist to Its Scientific Advisory Board

Abstract:
AlphaRx Inc. is pleased to announce the appointment of Dr. Donald Low to its Scientific Advisory Board (SAB), effective immediately. With more than 30 years of experience, Dr. Low is recognized world-wide as an authority in the area of emerging infectious diseases.

AlphaRx Appoints Leading Infectious Disease Specialist to Its Scientific Advisory Board

MARKHAM, ON, Canada | Posted on September 17th, 2008

Dr. Low is currently Head the Division of Microbiology, Department of Laboratory Medicine and Pathobiology at the in Toronto, Ontario. He is also Chief of University Health Network and Mount Sinai Hospital Department of Microbiology, as well as Professor for the Departments of Microbiology and Medicine at the . In addition, Dr. Low is Medical Director of the Public Health Laboratories for the Ontario Ministry of Health and Long-Term Care.

Dr. Low brings with him years of research experience in infectious diseases, particularly in new drug investigation, clinical trials design and implementation. The Scientific Advisory Board (SAB) will be instrumental in implementing AlphaRx's goal of advancing its lead pharmaceutical product Zysolin(TM) through clinical development.

About Zysolin(TM)

Zysolin(TM) is a Tobramycin compound, encapsulated in AlphaRx's Nano Drug Delivery Platform, intended for the adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients. Zysolin(TM) improves the intracellular activity of Tobramycin - in layman's term, increasing the drug concentration of Tobramycin inside human macrophages, thus improving its antibacterial activity against intracellular Klebsiella, Pseudomondas aeruginosa and Staphylococcus bacterial strains in pneumonia patients. The active ingredient in Zysolin(TM), Tobramycin, has a long-standing and proven clinical treatment record. Delivered by inhalation, using proprietary nanotechnology developed by AlphaRx, the company believes Zysolin(TM) will have an attractive safety, tolerability and efficacy profile when compared to injectable Tobramycin.

####

About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

FORWARD LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.

For more information, please click here

Contacts:
Agora Investor Relations Corp.

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

UT Dallas engineers twist nanofibers to create structures tougher than bulletproof vests March 27th, 2015

Novel nanoparticle therapy promotes wound healing March 27th, 2015

Designer's toolkit for dynamic DNA nanomachines: Arm-waving nanorobot signals new flexibility in DNA origami March 27th, 2015

Using magnetic fields to understand high-temperature superconductivity: Los Alamos explores experimental path to potential 'next theory of superconductivity' March 27th, 2015

Nanomedicine

Novel nanoparticle therapy promotes wound healing March 27th, 2015

Graphene reduces wear of alumina ceramic March 26th, 2015

Application of Graphene Oxide in Body Implants in Iran March 26th, 2015

Nanotechnology in Medical Devices Market is expected to reach $8.5 Billion by 2019 March 25th, 2015

Announcements

UT Dallas engineers twist nanofibers to create structures tougher than bulletproof vests March 27th, 2015

Novel nanoparticle therapy promotes wound healing March 27th, 2015

Designer's toolkit for dynamic DNA nanomachines: Arm-waving nanorobot signals new flexibility in DNA origami March 27th, 2015

Using magnetic fields to understand high-temperature superconductivity: Los Alamos explores experimental path to potential 'next theory of superconductivity' March 27th, 2015

Appointments/Promotions/New hires/Resignations/Deaths

Nanofilm Appoints Senior Sales/Marketing Executives: Don Tecco, Director of Optical Sales, North America and Rex Talbott, Business Director Optical Products March 23rd, 2015

KIT Increases Commitment in Asia: DAAD Funds Two New Projects: Strategic Partnerships with Chinese Universities and Communi-cation Technologies Network February 22nd, 2015

SouthWest Nanotechnologies CEO Dave Arthur Appointed to the Board of Affiliates of Rice University Professional Science Masterís Program February 13th, 2015

Nexeon Board Changes Announced January 29th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE